Monthly Publications
In Depth
Subscribe Now
In Depth
coverage of timely
Life Science
Compliance issues
Subscribe Now
Browsing Category
Congress
BioSimilars: FDA Panel Overwhelming Recommends Approval of Remicade…
Yesterday an FDA Advisory panel overwhelmingly recommended the Celltrion/Pfizer biosimilar Remsima 21-3 for approval for…
An Update on the Nomination of FDA Commissioner Robert Califf
An increasing number of senators are threatening to block Dr. Robert Califf's nomination to be the next Commissioner of…
Testy Oversight and Government Reform Committee Hearing on Prescription…
The United States House Oversight and Government Reform Committee held a hearing on developments in the prescription…
Senators Wyden and Grassley Request Public Comments on Gilead Pricing
On the heels of their December 1, 2015, report on Gilead Sciences' pricing of Hepatitis C drugs Sovaldi and Harvoni,…
Improving Regulatory Transparency for New Medical Therapies Act
President Obama recently signed the Improving Regulatory Transparency for New Medical Therapies Act into law. The Act…
Senate Aging Committee Hearing on Drug Prices: Faster Generics Approval…
The Senate Special Committee on Aging held a hearing on Wednesday, December 9, 2015, to discuss "Sudden Price Spikes in…
Senators McCain and Grassley Request HHS for Approval of Importation of…
As the controversy over drug pricing continues to heat up, Senators Chuck Grassley and John McCain have started to place…
Senate Finance Committee Releases Results of Investigation Into Gilead’s…
Senate Finance Committee Ranking Minority Member Ron Wyden and Republican member Charles Grassley released the results…
Stage III Meaningful Use CMS Doubles Down as Opposition Mounts
Despite Congressional interest in delaying Stage 3 of the electronic health record Meaningful Use program and the AMA…
House E&C Committee Turns Focus to the Regulation of Diagnostic Tests…
Background
The House Energy & Commerce Committee's Health Subcommittee held a hearing on November 17, 2015, to discuss a…